CUMBERLAND PHARMACEUTICALS INC
CPIX evidence brief
What we can confirm
- BioSniper Score:
- 8.5 / 10
- Market Cap:
- $115.7M
- Lead Asset:
- Dyscorban® (Phase 2)
What it means
What to watch
Prepared research question
What matters most for CPIX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CPIX
Cumberland Pharmaceuticals Inc. (CPIX) is a specialty pharmaceutical company with approved marketed products and a late-stage pipeline centered on ifetroban, a selective thromboxane-prostanoid receptor antagonist in Phase 2 trials for multiple indications.
Key risk: Low cash runway
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 3 clinical trials · 3 catalysts · 2 FDA decisions for CUMBERLAND PHARMACEUTICALS INC.
Cumberland Pharmaceuticals Inc. (CPIX) is a specialty pharmaceutical company with approved marketed products and a late-stage pipeline centered on ifetroban, a selective thromboxane-prostanoid receptor antagonist in Phase 2 trials for multiple indications.
- Cash & equivalents of $3.9M as of 2026-06-30 [sec]
- Net loss of $4.3M for the period ending 2026-06-30 [sec]
- Shareholders' equity of $17.4M as of 2026-06-30 [sec]
- Pipeline includes ifetroban (Vasculan®) in Phase 2 for systemic sclerosis, Duchenne muscular dystrophy cardiomyopathy, and idiopathic pulmonary fibrosis [pipeline]
- Approved product omeclamox-pak (amoxicillin/clarithromycin/omeprazole) [pipeline]
What works
- Revenue growth across its marketed portfolio and continued international expansion were reported in 2025 and early 2026 [news · published 2026-03-03]
- Ifetroban has Orphan Drug Designation and Rare Pediatric Disease Designation for Duchenne muscular dystrophy cardiomyopathy [pipeline]
- Expanded indication for Caldolor (ibuprofen) injection received in April 2026 [news · published 2026-04-16]
What to weigh
- Net loss of $4.3M as of 2026-06-30 indicates ongoing operating losses [sec]
- Cash & equivalents of only $3.9M as of 2026-06-30 suggests limited financial runway [sec]
- Pivot into drug development creates both risk and opportunity, with clinical development subject to factors outside the company's control [news · published 2026-08-13]
- Ifetroban faces a competitive landscape with multiple Phase 2 and Phase 3 competitors in systemic sclerosis and idiopathic pulmonary fibrosis [pipeline]
From the filings
Quoted directly from source documents.
Ifetroban is in Phase 2 for systemic sclerosis
“Pipeline Candidate: Vasculan® Generic Name: ifetroban Indication: Systemic Sclerosis (SSc) Phase: Phase 2”
Expanded indication for Caldolor in April 2026
“Cumberland Pharmaceuticals has received an expanded indication for its Caldolor ibuprofen injection.”
News · April 16, 2026
Catalyst timeline
- 2027-01-01 · Patent_Expiry · TELAVANCIN HYDROCHLORIDE — Patent expiry for NDA022110; may open market to generic competition.
- 2032-03-16 · Patent_Expiry · IBUPROFEN — Patent expiry for NDA022348; potential generic entry for ibuprofen products.
- 2032-04-06 · Patent_Expiry · ACETYLCYSTEINE — Patent expiry for NDA021539; may affect acetylcysteine product exclusivity.
Risks & what to watch (4)›
Key risks
- Low cash runway — Cash & equivalents of $3.9M as of 2026-06-30 may be insufficient to fund operations and pipeline development without additional financing [sec]
- Operating losses persist — Net loss of $4.3M for the period ending 2026-06-30 indicates ongoing negative cash flow [sec]
- Pipeline competition — Ifetroban faces multiple Phase 2/3 competitors in systemic sclerosis and idiopathic pulmonary fibrosis [pipeline]
- Clinical development risks — All phases of operations are subject to factors outside the company's control, including clinical trial outcomes and regulatory review [news · published 2026-08-28]
What to watch
- Progress of ifetroban Phase 2 trials in systemic sclerosis, Duchenne muscular dystrophy cardiomyopathy, and idiopathic pulmonary fibrosis [pipeline]
- Impact of the planned strategic transaction with Apotex on marketed products and cash position [news · published 2026-05-05]
- Patent expiry of TELAVANCIN HYDROCHLORIDE on 2027-01-01, which may affect competitive landscape [catalyst]
- Revenue growth trajectory from marketed brands and international expansion [news · published 2026-03-03]
Sources: Catalysts · News · Pipeline · Generated October 12, 2026 · How we verify sources →
Run CUMBERLAND PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CUMBERLAND PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 2.62 · 0% dilution
Lead: Approved
6 candidates
3 upcoming, next in ~80d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 6.0%
- Days to cover
- 0.2
- Shares short
- 523,399
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CPIX short interestGovernance
Frequently asked questions
What is the AI investment thesis for CUMBERLAND PHARMACEUTICALS INC?
Cumberland Pharmaceuticals Inc. (CPIX) is a specialty pharmaceutical company with approved marketed products and a late-stage pipeline centered on ifetroban, a selective thromboxane-prostanoid receptor antagonist in Phase 2 trials for multiple indications.
What is CUMBERLAND PHARMACEUTICALS INC's lead drug candidate?
CUMBERLAND PHARMACEUTICALS INC's most advanced tracked candidate is Dyscorban® (Phase 2) for cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
What is CUMBERLAND PHARMACEUTICALS INC's next catalyst?
CUMBERLAND PHARMACEUTICALS INC's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA022110" — expected January 1, 2027.
Who is the CEO of CUMBERLAND PHARMACEUTICALS INC?
Mr. A. J. Kazimi MBA is the chief executive officer of CUMBERLAND PHARMACEUTICALS INC (CPIX).
Where is CUMBERLAND PHARMACEUTICALS INC headquartered?
CUMBERLAND PHARMACEUTICALS INC (CPIX) is headquartered in Nashville, TN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.